Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management

References

• Adams R, Maroof A, Baker T, Lawson ADG, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, et al. 2020. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 11:1894. doi: 10.3389/fimmu.2020.01894.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Blauvelt A, Mrowietz U, Strober B, Gisondi P, Merola JF, Langley RG, Ståhle M, Lebwohl M, Netea MG, et al. 2022. A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17. Dermatol Ther (Heidelb). 12(3):787–800. doi:10.1007/s13555-022-00687-0.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Bukhalo M, Blauvelt A. 2016. A clinician’s guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol. 17(4):329–336. doi: 10.1007/s40257-016-0206-4.
   PubMed Web of Science ®Google Scholar
• Azadeh H, Alizadeh-Navaei R, Rezaiemanesh A, Rajabinejad M. 2022. Immune-related adverse events (irAes) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: A systematic review and meta-analysis. Inflammopharmacol. 30(2):435–451. doi: 10.1007/s10787-022-00933-z.
   PubMed Web of Science ®Google Scholar
• Basmaciyan L, Bon F, Paradis T, Lapaquette P, Dalle F. 2019. Candida albicans interactions with the host: Crossing the intestinal epithelial barrier. Tissue Barriers. 7(2):1612661. doi: 10.1080/21688370.2019.1612661.
   PubMed Web of Science ®Google Scholar
• Bastid J, Dejou C, Docquier A, Bonnefoy N. 2020. The emerging role of the IL-17B/IL-17RB pathway in cancer. Front Immunol. 11:718. doi: 10.3389/fimmu.2020.00718.
   PubMed Web of Science ®Google Scholar
• Berry SPD, Dossou C, Kashif A, Sharifinejad N, Azizi G, Hamedifar H, Sabzvari A, Zian Z. 2022. The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases. Int Immunopharmacol. 102:108402. doi: 10.1016/j.intimp.2021.108402.
   PubMed Web of Science ®Google Scholar
• Bianchi E, Rogge L. 2019. The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies. Genes Immun. 20(5):415–425. doi: 10.1038/s41435-019-0067-y.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaçi D, Toth D, Messina I, You R, Guana A, Fox T, Papavassilis C, Gilloteau I, et al. 2017. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 177(4):1033–1042. doi: 10.1111/bjd.15706.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, ElMaraghy H, Patel H, Ridenour T, See K, et al. 2021. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 85(2):360–368. doi:10.1016/j.jaad.2020.11.022.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, Wang M, Cioffi C, Griffiths CEM. 2020. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 83(5):1367–1374. doi: 10.1016/j.jaad.2020.05.105.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S. 2015. Secukinumab administration by pre-filled syringe: Efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 172(2):484–493. doi: 10.1111/bjd.13348.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Brembilla NC. 2022. Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opin Biol Ther. 22(12):1463–1473. doi: 10.1080/14712598.2022.2100219.
   PubMed Web of Science ®Google Scholar
• Bojang E, Ghuman H, Kumwenda P, Hall RA. 2021. Immune sensing of Candida albicans. J Fungi. 7(2):10.3390/jof7020119. doi: 10.3390/jof7020119.
   Web of Science ®Google Scholar
• Brevi A, Cogrossi LL, Grazia G, Masciovecchio D, Impellizzieri D, Lacanfora L, Grioni M, Bellone M. 2020. Much more than IL-17A: Cytokines of the IL-17 family between microbiota and cancer. Front Immunol. 11:565470. doi: 10.3389/fimmu.2020.565470.
   PubMed Web of Science ®Google Scholar
• Brodalumab. 2006. Drugs and lactation database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development.
   Google Scholar
• Bruno M, Davidson L, Koenen H, van den Reek J, van Cranenbroek B, de Jong E, van de Veerdonk FL, Kullberg BJ, Netea MG. 2022. Immunological effects of anti‒IL-17/12/23 therapy in patients with psoriasis complicated by Candida infections. J Invest Dermatol. 142(11):2929–2939.e2928. doi: 10.1016/j.jid.2022.05.1083.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin SL. 2013. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 188(11):1294–1302. doi: 10.1164/rccm.201212-2318OC.
   PubMed Web of Science ®Google Scholar
• Cao Z, Liu Z, Zhu X, Yang Q, Xu Q, Zhang C. 2022. Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis. Ren Fail. 44(1):826–830. doi: 10.1080/0886022x.2022.2073893.
   PubMed Web of Science ®Google Scholar
• Chang SH. 2019. T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer. Arch Pharm Res. 42(7):549–559. doi: 10.1007/s12272-019-01146-9.
   PubMed Web of Science ®Google Scholar
• Combe B, Rahman P, Kameda H, Cañete JD, Gallo G, Agada N, Xu W, Genovese MC. 2020. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 22(1):14. doi: 10.1186/s13075-020-2099-0.
   PubMed Web of Science ®Google Scholar
• Craig S, Warren RB. 2020. Ixekizumab for the treatment of psoriasis: up-to-date. Expert Opin Biol Ther. 20(6):549–557. doi: 10.1080/14712598.2020.1729736.
   PubMed Web of Science ®Google Scholar
• Davidson L, van den Reek J, Bruno M, van Hunsel F, Herings RMC, Matzaraki V, Boahen CK, Kumar V, Groenewoud HMM, van de Veerdonk FL, et al. 2022. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Reg Health Eur. 13:100266. doi: 10.1016/j.lanepe.2021.100266.
   PubMedGoogle Scholar
• d’Enfert C, Kaune AK, Alaban LR, Chakraborty S, Cole N, Delavy M, Kosmala D, Marsaux B, Fróis-Martins R, Morelli M, et al. 2021. The impact of the fungus-host-microbiota interplay upon Candida albicans infections: Current knowledge and new perspectives. FEMS Microbiol Rev. 45(3): doi:10.1093/femsre/fuaa060
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhou B, Wang Z, Xu G, Wang L, Zhang T, Zhang Y, Poddighe D. 2022. Risk of Candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: A systematic review and meta-analysis of randomized controlled trials. Int J Clin Pract. 2022:1–11. doi: 10.1155/2022/2442603.
   Web of Science ®Google Scholar
• Finkina EI, IV B, AA I, Kanushkina MD, Egorova EA, Voropaev AD, Stukacheva EA, Ovchinnikova TV. 2022. Antifungal activity, structural stability, and immunomodulatory effects on human immune cells of defensin from the lentil lens culinaris. Membranes. 12(9):855. doi: 10.3390/membranes12090855.
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Warren RB. 2019. Brodalumab in psoriasis: Evidence to date and clinical potential. Drugs Context. 8:212570. doi: 10.7573/dic.212570.
   PubMedGoogle Scholar
• Frieder J, Kivelevitch D, Menter A. 2018. Secukinumab: A review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 9(1):5–21. doi: 10.1177/2040622317738910.
   PubMed Web of Science ®Google Scholar
• Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, Ozawa A, Kanekura T, Kurosawa M, Komine M, et al. 2018. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 45(11):1235–1270. doi:10.1111/1346-8138.14523.
   PubMed Web of Science ®Google Scholar
• Gaffen SL, Moutsopoulos NM. 2020. Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity. Sci Immunol. 5(43):eaau4594. doi: 10.1126/sciimmunol.aau4594.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. 2020. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 20(2):173–182. doi: 10.1080/14712598.2020.1708897.
   PubMed Web of Science ®Google Scholar
• Gaspari AA, Tyring S. 2015. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: Mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 28(4):179–193. doi: 10.1111/dth.12251.
   PubMed Web of Science ®Google Scholar
• González-Fernández C, Chaves-Pozo E, Cuesta A. 2020. Identification and regulation of interleukin-17 (IL-17) family ligands in the teleost fish European sea bass. Int J Mol Sci. 21(7):2439. doi: 10.3390/ijms21072439.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Colombel JF, Hardin DS, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, et al. 2016. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 375(4):345–356. doi: 10.1056/NEJMc1610828.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, et al. 2021. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 397(10273):475–486. doi:10.1016/S0140-6736(21)00126-4.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C. 2016. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the FEATURE trial. J Drugs Dermatol JDD. 15(10):1226–1234.
   PubMed Web of Science ®Google Scholar
• Griffith SK, Ahn GS, Wu JJ. 2021. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 385(12):1149–1150. doi: 10.1056/NEJMc2113092.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, et al. 2015. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet. 386(9993):541–551. doi:10.1016/s0140-6736(15)60125-8.
   PubMed Web of Science ®Google Scholar
• Huppler AR, Bishu S, Gaffen SL. 2012. Mucocutaneous candidiasis: The IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 14(4):217. doi: 10.1186/ar3893.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, Nakae S. 2011. Functional specialization of interleukin-17 family members. Immunity. 34(2):149–162. doi: 10.1016/j.immuni.2011.02.012.
   PubMed Web of Science ®Google Scholar
• Ixekizumab. 2006. Drugs and lactation database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development.
   Google Scholar
• Jiang P, Zheng C, Xiang Y, Malik S, Su D, Xu G, Zhang M. 2023. The involvement of TH17 cells in the pathogenesis of IBD. Cytokine Growth Factor Rev. 69:28–42. doi: 10.1016/j.cytogfr.2022.07.005.
   PubMed Web of Science ®Google Scholar
• Kearns DG, Uppal S, Chat VS, Wu JJ. 2021. Comparison of guidelines for the use of interleukin-17 inhibitors for psoriasis in the United States, Britain, and Europe: A critical appraisal and comprehensive review. J Clin Aesthet Dermatol. 14(6):55–59.
   PubMedGoogle Scholar
• Lacour JP, Paul C, Jazayeri S, Papanastasiou P, Xu C, Nyirady J, Fox T, Papavassilis C. 2017. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: Results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 31(5):847–856. doi: 10.1111/jdv.14073.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, et al. 2014. Secukinumab in plaque psoriasis — Results of two phase 3 trials. N Engl J Med. 371(4):326–338. doi:10.1056/NEJMoa1314258.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, et al. 2015. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 373(14):1318–1328. doi: 10.1056/NEJMoa1503824.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Sator P, Morita A, Kokolakis G, Blauvelt A, Warren R, De Cuyper D, Madden C, Vanvoorden V, Wang M. 2022. Bimekizumab efficacy and safety up to two years in patients with moderate to severe plaque psoriasis switching from ustekinumab: Results from the interim BE BRIGHT open-label extension trial. Australas J Dermatol. 63:13–14.
   Web of Science ®Google Scholar
• Li T, Liu Y, Yu X, Wang P, Sun S, Liu D. 2022. IL-17D affects the chemokines and chemokine receptors of intestinal epithelial cells under hyperoxia. Int Immunopharmacol. 113(Pt A):109386. doi: 10.1016/j.intimp.2022.109386.
   PubMedGoogle Scholar
• Li Z, Lu G, Meng G. 2019. Pathogenic fungal infection in the lung. Front Immunol. 10:1524. doi: 10.3389/fimmu.2019.01524.
   PubMed Web of Science ®Google Scholar
• Ling Y, Puel A. 2014. IL-17 and infections. Actas Dermosifiliogr. 105(1):34–40. doi: 10.1016/S0001-7310(14)70016-X.
   PubMedGoogle Scholar
• Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, Barmettler B, Nelson J, Bina H, Huang L, et al. 2016. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. JIR. 9:39–50. doi: 10.2147/jir.s100940.
   Google Scholar
• Lopes JP, Lionakis MS. 2022. Pathogenesis and virulence of Candida albicans. Virulence. 13(1):89–121. doi: 10.1080/21505594.2021.2019950.
   PubMed Web of Science ®Google Scholar
• Matsuzaki G, Umemura M. 2018. Interleukin-17 family cytokines in protective immunity against infections: Role of hematopoietic cell-derived and non-hematopoietic cell-derived interleukin-17s. Microbiol Immunol. 62(1):1–13. doi: 10.1111/1348-0421.12560.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, et al. 2020. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 79(1):123–131. doi: 10.1136/annrheumdis-2019-215386.
   PubMed Web of Science ®Google Scholar
• Mills KHG. 2023. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 23(1):38–54. doi: 10.1038/s41577-022-00746-9.
   PubMed Web of Science ®Google Scholar
• Miura S, Garcet S, Li X, Cueto I, Salud-Gnilo C, Kunjravia N, Yamamura K, Gonzalez J, Murai-Yamamura M, Rambhia D, et al. 2023. Cathelicidin antimicrobial peptide LL37 induces toll-like receptor 8 and amplifies IL-36γ and IL-17C in human keratinocytes. Journal Of Investigative Dermatology. 143(5):832–841.e834. doi:10.1016/j.jid.2022.10.017.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, Szepietowski JC, Regnault P, Thurston H, Papavassilis C. 2015. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 73(1):27–36.e21. doi: 10.1016/j.jaad.2015.04.011.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niiro H, Ootaki K. 2016. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 81(1):44–52. doi: 10.1016/j.jdermsci.2015.10.009.
   PubMed Web of Science ®Google Scholar
• Nie YJ, Wu SH, Xuan YH, Yan G. 2022. Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis. Mil Med Res. 9(1):21. doi: 10.1186/s40779-022-00382-3.
   PubMed Web of Science ®Google Scholar
• Notario J, Deza G, Vilarrasa E, Valentí F, Muñoz C, Mollet J, Rocamora V, Carrascosa JM, Del Alcázar E, Alsina M, et al. 2019. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: A 52-week, multicenter, retrospective study in Spain. J Dermatol Treat. 30(5):424–429. doi:10.1080/09546634.2018.1528000.
   PubMed Web of Science ®Google Scholar
• Okada S, Puel A, Casanova JL, Kobayashi M. 2016. Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity. Clin Transl Immunol. 5(12):e114. doi: 10.1038/cti.2016.71.
   PubMedGoogle Scholar
• Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, et al. 2016. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 62(4):e1–50. doi: 10.1093/cid/civ933.
   PubMed Web of Science ®Google Scholar
• Papp K, Menter A, Leonardi C, Soung J, Weiss S, Pillai R, Jacobson A. 2020. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: Subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 183(6):1037–1048. doi: 10.1111/bjd.19132.
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A. 2018. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 79(2):277–286.e210. doi: 10.1016/j.jaad.2018.03.037.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, et al. 2016. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 175(2):273–286. doi: 10.1111/bjd.14493.
   PubMed Web of Science ®Google Scholar
• Pathakumari B, Liang G, Liu W. 2020. Immune defence to invasive fungal infections: A comprehensive review. Biomed Pharmacother. 130:110550. doi: 10.1016/j.biopha.2020.110550.
   PubMed Web of Science ®Google Scholar
• Patrikiou E, Liaskos C, Mavropoulos A, Ntavari N, Gkoutzourelas A, Simopoulou T, Fechner K, Scheper T, Meyer W, Katsiari CG, et al. 2020. Autoantibodies against specific nuclear antigens are present in psoriatic disease and are diminished by secukinumab. Clin Chim Acta. 510:400–407. doi: 10.1016/j.cca.2020.07.037.
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C. 2015. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: A randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 29(6):1082–1090. doi: 10.1111/jdv.12751.
   PubMed Web of Science ®Google Scholar
• Peroumal D, Sahu SR, Kumari P, Utkalaja BG, Acharya N, Alanio A. 2022. Commensal fungus Candida albicans maintains a long-term mutualistic relationship with the host to modulate gut microbiota and metabolism. Microbiol Spectr. 10(5):e0246222. doi: 10.1128/spectrum.02462-22.
   PubMed Web of Science ®Google Scholar
• Perrotta FM, Scriffignano S, Ciccia F, Lubrano E. 2022. Therapeutic targets for ankylosing spondylitis - Recent insights and future prospects. Open Access Rheumatol Res Rev. 14:57–66. doi: 10.2147/oarrr.s295033.
   PubMed Web of Science ®Google Scholar
• Pettas E, Savva V, Theofilou VI, Georgaki M, Nikitakis NG. 2021. Oral Candida infection in psoriatic patients treated with IL17A inhibitors: Report of 3 cases and a comprehensive review of the literature. Diagnostics. 12(1). doi: 10.3390/diagnostics12010003.
   Web of Science ®Google Scholar
• Pinter A, Bonnekoh B, Hadshiew IM, Zimmer S. 2019. Brodalumab for the treatment of moderate-to-severe psoriasis: Case series and literature review. Clin Cosmet Investig Dermatol. 12:509–517. doi: 10.2147/ccid.s211938.
   PubMed Web of Science ®Google Scholar
• Pountain AW, Collette JR, Farrell WM, Lorenz MC, Goldman GH. 2021. Interactions of both pathogenic and nonpathogenic CUG clade Candida species with macrophages share a conserved transcriptional landscape. mBio. 12(6):e0331721. doi: 10.1128/mbio.03317-21.
   PubMed Web of Science ®Google Scholar
• Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, et al. 2011. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Sci. 332(6025):65–68. doi: 10.1126/science.1200439.
   PubMed Web of Science ®Google Scholar
• Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. 2020. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 82(2):352–359. doi: 10.1016/j.jaad.2019.05.095.
   PubMed Web of Science ®Google Scholar
• Rafael-Vidal C, Pérez N, Altabás I, Garcia S, Pego-Reigosa JM. 2020. Blocking IL-17: A promising strategy in the treatment of systemic rheumatic diseases. Int J Mol Sci. 21(19). doi: 10.3390/ijms21197100.
   Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, et al. 2021. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 397(10273):487–498. doi:10.1016/S0140-6736(21)00125-2.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, et al. 2021. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 385(2):142–152. doi: 10.1056/NEJMoa2102383.
   PubMed Web of Science ®Google Scholar
• Rioux G, Simard M, Morin S, Lorthois I, Guérin SL, Pouliot R. 2021. Development of a 3D psoriatic skin model optimized for infiltration of IL-17A producing T cells: Focus on the crosstalk between T cells and psoriatic keratinocytes. Acta Biomater. 136:210–222. doi: 10.1016/j.actbio.2021.09.018.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, Gottlieb AB, Assudani D, Bedford-Rice K, Coarse J, et al. 2020. Bimekizumab in patients with active psoriatic arthritis: Results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 395(10222):427–440. doi:10.1016/S0140-6736(19)33161-7.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Cerdeira C, González-Cespón JL, Martínez-Herrera E, Carnero-Gregorio M, López-Barcenas A, Sergeev A, Saunte DM. 2021. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Ital J Dermatol Venereol. 156(5):545–557. doi: 10.23736/S2784-8671.20.06580-3.
   PubMedGoogle Scholar
• Ruggiero A, Megna M, Fabbrocini G, Fornaro L, Villani A. 2022. Drug safety evaluation of ixekizumab for psoriasis: A review of the current knowledge. Expert Opin Drug Saf. 21(10):1249–1257. doi: 10.1080/14740338.2022.2134855.
   PubMed Web of Science ®Google Scholar
• Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, Juanatey CG, Adán A, Montalbán X, Borruel N, et al. 2020. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 19(1):102429. doi: 10.1016/j.autrev.2019.102429.
   PubMed Web of Science ®Google Scholar
• Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Sano S, Torii H, et al. 2023. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 50(2):e41–e68. doi:10.1111/1346-8138.16691.
   PubMed Web of Science ®Google Scholar
• Saini C, Sapra L, Bhardwaj A, Tarique M, Sharma A, Khanna N, Ramesh V, Puri P, Srivastava RK. 2022. IL-21 plays an important role in modulating “Th17-treg” cell axis in leprosy type 1 reactions. Cytokine. 152:155821. doi: 10.1016/j.cyto.2022.155821.
   PubMed Web of Science ®Google Scholar
• Sanford M, McKeage K. 2015. Secukinumab: First global approval. Drugs. 75(3):329–338. doi: 10.1007/s40265-015-0359-0.
   PubMed Web of Science ®Google Scholar
• Sawada Y, Setoyama A, Sakuragi Y, Saito-Sasaki N, Yoshioka H, Nakamura M. 2021. The role of IL-17-producing cells in cutaneous fungal infections. Int J Mol Sci. 22(11). doi: 10.3390/ijms22115794.
   Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, et al. 2020. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database Syst Re. 1(1):Cd011535. doi: 10.1002/14651858.CD011535.pub3.
   PubMedGoogle Scholar
• Shao TY, Haslam DB, Bennett RJ, Way SS. 2022. Friendly fungi: Symbiosis with commensal Candida albicans. Trends Immunol. 43(9):706–717. doi: 10.1016/j.it.2022.07.003.
   PubMed Web of Science ®Google Scholar
• Silfvast-Kaiser A, Paek SY, Menter A. 2019. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 19(1):45–54. doi: 10.1080/14712598.2019.1555235.
   PubMed Web of Science ®Google Scholar
• Srinivas C, Odsbu I, Linder M. 2020. Risk of common infections among individuals with psoriasis in Sweden: A nationwide cohort study comparing secukinumab to ustekinumab. Pharmacoepidemiol Drug Saf. 29(12):1562–1569. doi: 10.1002/pds.5132.
   PubMed Web of Science ®Google Scholar
• Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, Kotris I, Škrlec I. 2021. Candida albicans—The virulence factors and clinical manifestations of infection. J Fungi. 7(2):79. doi: 10.3390/jof7020079.
   Web of Science ®Google Scholar
• Tangye SG, Puel A. 2023. The Th17/IL-17 axis and host defense against fungal infections. J Allergy Clin Immunol Pract. 11(6):1624–1634. doi: 10.1016/j.jaip.2023.04.015.
   PubMed Web of Science ®Google Scholar
• Toussirot E. 2012. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 11(2):159–168. doi: 10.2174/187152812800392805.
   PubMedGoogle Scholar
• van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, et al. 2018. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 392(10163):2441–2451. doi: 10.1016/s0140-6736(18)31946-9.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gensler LS, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A, Farmer MK, Baeten D, Goldammer N, Coarse J, et al. 2020. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 79(5):595–604. doi: 10.1136/annrheumdis-2020-216980.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitenberg G, Nyström PO, Pittet D, et al. 1998. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med. 24(3):206–216. doi: 10.1007/s001340050552.
   PubMed Web of Science ®Google Scholar
• Wang SS, Tang YL, Pang X, Zheng M, Tang YJ, Liang XH. 2019. The maintenance of an oral epithelial barrier. Life Sci. 227:129–136. doi: 10.1016/j.lfs.2019.04.029.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang C, Liu L, Hong S, Ru Y, Sun X, Chen J, Zhang M, Lin N, Li B, et al. 2023. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: A systematic scoping review. Front Immunol. 14:993057. doi: 10.3389/fimmu.2023.993057.
   PubMed Web of Science ®Google Scholar
• Wilharm A, Binz C, Sandrock I, Rampoldi F, Lienenklaus S, Blank E, Winkel A, Demera A, Hovav AH, Stiesch M, et al. 2022. Interleukin-17 is disease promoting in early stages and protective in late stages of experimental periodontitis. PloS One. 17(3):e0265486. doi:10.1371/journal.pone.0265486.
   PubMed Web of Science ®Google Scholar
• Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. 2021. Sexually transmitted infections treatment guidelines, 2021. MMWR Recommend Reports: Morbidity And Mortality Weekly Report Recommend Rep. 70(4):1–187. doi: 10.15585/mmwr.rr7004a1.
   PubMedGoogle Scholar
• Yamanaka-Takaichi M, Ghanian S, Katzka DA, Torgerson RR, Alavi A. 2022. Candida infection associated with anti-IL-17 medication: A systematic analysis and review of the literature. Am J Clin Dermatol. 23(4):469–480. doi: 10.1007/s40257-022-00686-z.
   PubMed Web of Science ®Google Scholar
• Yeung J, Bunce PE, Lynde CW, Turchin I, Vender RB. 2022. Review and practical guidance on managing fungal infections in patients with psoriasis receiving anti-IL-17 therapies. J Cutan Med Surg. 26(1_suppl):3s–23s. doi: 10.1177/12034754221111111.
   PubMed Web of Science ®Google Scholar
• Yin Y, Wang M, Liu M, Zhou E, Ren T, Chang X, He M, Zeng K, Guo Y, Wu J. 2020. Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: A systematic review and meta-analysis. Arthritis Res Ther. 22(1):111. doi: 10.1186/s13075-020-02208-w.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Peng N, Xiao F, Shi X, Zhu B, Rui K, Tian J, Lu L. 2023. New insights into the function of interleukin-25 in disease pathogenesis. Biomark Res. 11(1):36. doi: 10.1186/s40364-023-00474-9.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liao Y, Liu Z, Dai Y, Li Y, Li Y, Tang Y. 2021. Interleukin-17 and ischaemic stroke. Immunology. 162(2):179–193. doi: 10.1111/imm.13265.
   PubMed Web of Science ®Google Scholar